Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia

• Published in: Experimental Oncology
• Date: 2014
• Main Authors: Horacek, J.M., Kupsa, T., Vasatova, M., Jebavy, L., Zak, P.
• Format: Article
• Language: English
• Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
• Subjects: Short communications
• Online Access: https://nasplib.isofts.kiev.ua/handle/123456789/145330
• Journal Title: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Cite this: Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia / J.M. Horacek, T. Kupsa, M. Vasatova, L. Jebavy, P. Zak // Experimental Oncology. — 2014. — Т. 36, № 1. — С. 50-51. — Бібліогр.: 16 назв. — англ.

Aim: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and in healthy subjects using biochip array technology. Methods: A total of 15 AML patients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. Results: In newly diagnosed AML patients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and significant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines and adhesion molecules. Conclusion: Our results indicate that serum levels of specific cytokines and adhesion molecules ­(­VCAM-1, ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed to define the potential role of these and additional markers in the risk stratification of AML. Key Words: cytokines, adhesion molecules, biochip array, acute myeloid leukemia.